# Stargardt disease

Type: Technology

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/stargardt-disease
Canonical HTML page: https://getbiobrief.com/entity/stargardt-disease

## Timeline

- **2026-12-31**: Commercialization Ramp-up — Planned $200M-$250M expenditure for market entry and launch preparation.
- **2026-06-30**: Target NDA Submission — Company plans to submit New Drug Application to the FDA by the end of Q2 2026.
- **2026-03-10**: Phase 3 Data Release — Belite Bio details 36% lesion growth reduction at Leerink conference.

## Recent coverage (1 stories)

### Belite Bio's Tinlarebant Slows Stargardt Lesion Growth by 36% in Phase 3
2026-03-11 00:45:48 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Belite Bio (BLTE) has reported positive Phase 3 DRAGON trial results for its lead candidate, Tinlarebant, demonstrating a 36% reduction in lesion growth for Stargardt disease. The oral therapy is now positioned for a Q2 2026 NDA submission as the company prepares for a $200M-$250M commercial launch.
Full story: https://getbiobrief.com/story/belite-bio-tinlarebant-stargardt-phase-3-results

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.